Emergent BioSolutions | EBS - Les Intérêts Débiteurs Sur La Dette





Les Intérêts Débiteurs Sur La Dette Changement Date
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 349.66M 12.86M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 3.64M 775K 2026-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Coherus Biosciences USD 2.25M 76K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
Lonza CHF 84M 14M 2025-06
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Myriad Genetics USD 4.4M 600K 2025-12
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pacira USD 3.62M 77K 2026-06
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sanofi EUR 287M 109M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
United Therapeutics USD 2.9M 200K 2026-06
Vanda Pharmaceuticals -1.37B 1.97B 2025-12